Several studies have focused on the association between the ERCC2 rs13181 polymorphism and glioma risk, but the results were inconclusive. We aimed to conduct a meta-analysis to investigate the role of ERCC2 rs13181 on the risk of glioma. We searched and collated the relevant studies in both Chinese and English through the PubMed, Web of Science, Cochrane Library, and EMBASE databases published through June 1, 2014. A total of 11 studies for ERCC2 rs13181 were selected; these included 3456 glioma cases and 4957 controls. Using fixed-effects model analysis, we found that no significant difference could be identified between the ERCC2 rs13181 polymorphism and the risk of glioma. Subgroup analysis showed that the ERCC2 rs13181 GT and TT genotypes were significantly associated with an increased risk of glioma in the Chinese population [odds ratio (OR) = 1.47, 95% confidence interval (CI) = 1.17-1.85; and OR = 1.50, 95%CI = 1.02-2.22, respectively], but no significant increased risk of glioma was detected with these genotypes in the Caucasian populations. No publication bias was identified in this meta-analysis. Our meta-analysis strongly suggested that ERCC2 rs13181 was associated with a higher susceptibility to glioma in the Chinese population.